Authors: Kabarra K, Golabi P, Younossi ZM.
Published in Endocr Connect 2021
In this review, the authors focus on NAFLD / NASH and its clinical, economical, and patient related burdens.Read More
Authors: Ramírez-Mejía MM, Díaz-Orozco LE, Barranco-Fragoso B, et al.
Published in Med Sci Monit 2021
MAFLD is the most common cause of chronic liver disease in children and adolescents. The risk factors for MAFLD may be prenatal, such as genetic factors, or postnatal, such as obesity and insulin resistance. MAFLD is increasingly recognized in children and adolescents...
Authors: Yilmaz Y, Byrne CD, Musso G.
Published in Expert Rev Gastroenterol Hepatol 2021
Recently, a consensus recommended 'metabolic (dysfunction) associated fatty liver disease' as a more appropriate name to describe fatty liver disease associated with metabolic dysfunction (MAFLD). This single-letter change in the NAFLD acronym suggests that the old acronyms should be abandoned...Read More
Authors: Fouad Y, Elwakil R, Elsahhar M, et al.
Published in Liver Int 2021
Polarising opinions and major debate have recently arisen in hepatology on the nomenclature and diagnostic criteria for fatty liver disease associated with metabolic dysfunction.The aim of this viewpoint by Y. Fouad et al. (Faculty of Medicine, Minia University, Egypt) is to suggest...
Authors: Younossi ZM, Rinella ME, Sanyal AJ, et al.
Published in Hepatology 2021
Despite the substantial gains in our understanding of NAFLD/NASH over the past 2 decades, there has been some dissatisfaction with the terminology “non-alcoholic” which overemphasises “alcohol” and underemphasises the predisposing metabolic risk factors. The term MAFLD is still suboptimal, leaving a great deal of ambiguity...
Authors: Cariou B, Byrne CD, Loomba R, et al.
Published in Diabetes Obes Metab 2021
A systematic literature review to identify recent epidemiological, biomarker, genetic and clinical evidence that expands our understanding of NAFLD as a metabolic disorder was performed by B. Cariou et al. (Inserm, CNRS, France). It appears that here is a growing body of evidence on the links between NAFLD/NASH pathogenesis and mechanisms of metabolic dysfunction...
Authors: Zhou YJ, Zheng KI, Targher G, et al.
Published in Lancet Gastroenterol Hepatol 2021
For Y. J. Zhou, et al., there is an urgent need to identify patients who are at risk of developing NASH. Traditional, non-invasive tests have been developed to identify either NASH or advanced fibrosis. However, these tests do not accurately detect patients who are at risk of NASH. Harrison et al. developed and validated the NIS4 test that provides...
Authors: Abdelmalek MF.
Published in Nat Rev Gastroenterol Hepatol 2021
he field of NAFLD and its progressive form, NASH, has, despite the challenges of the COVID-19 pandemic, continued to rapidly evolve in 2020. There have been substantial advances in NAFLD mechanisms, diagnostics, and treatment. Key developments include the identification of a multiparametric cellular and tissue signature to define disease progression...
Authors: Eslam M, Sanyal AJ, George J, et al.
Published in Gastroenterology 2020
The exclusion of other chronic liver diseases including “excess” alcohol intake are usually necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver disease (MAFLD). However, “positive criteria” to diagnose the disease are required. A panel of international experts from 22 countries...